Brief: Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
21/01/2026 13:02
Jan 21 (Reuters) - Aligos Therapeutics Inc ALGS.O: ALIGOS THERAPEUTICS PROVIDES PHASE 2 B-SUPREME STUDY PROGRESS UPDATES ALIGOS THERAPEUTICS INC: STUDY REMAINS ON TRACK TO COMPLETE ENROLLMENT, WITH TOPLINE DATA EXPECTED IN 2027 Source text: ID:nGNX5yCFlw Further company coverage: ALGS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue